Page 30 - Johnson Medtech News Today

A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ -- Biosense Webster, Inc., part of Johnson & Johnson MedTech[], today announced the release of a report titled, 'Atrial Fibrillation Exacts Toll on Women: Addressing the Gender Disparity in the Treatment and Management of Atrial Fibrillation in the Asia-Pacific Region'. Endors...

/PRNewswire/ -- CERENOVUS, Inc., part of Johnson & Johnson MedTech*, today announced positive primary outcomes from the real-world EXCELLENT Registry focused...

/PRNewswire/ -- CERENOVUS, Inc., part of Johnson & Johnson MedTech*, today announced positive primary outcomes from the real-world EXCELLENT Registry focused...

/PRNewswire/ -- The vascular embolization devices market is expected to grow by USD 569.63 million during 2021-2026, progressing at a CAGR of 5.83% during the...

/PRNewswire/ -- Keurig Dr Pepper (NASDAQ: KDP) today announced that Oray Boston, Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal...

Johnson & Johnson (“J&J”) announced on November 1, 2022, that it will acquire Abiomed for an upfront payment of $380.00 per share in cash, which equates to about $16.6 billion. The...

Investigators Compared AFib Patients Treated with Catheter Ablation to Those Treated with Anti-arrhythmic Drugs Only

Johnson & Johnson MedTech named Ahmet Tezel as company group chairman and global head of Innovation and R&D.

The upfront payment for all shares of the company, which specializes in technologies for heart recovery, is valued at $16.6B.

/PRNewswire/ -- From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China. He will head the leadership team...